Disease / condition
Carcinoma, Non-Small-Cell Lung clinical trials
Free access to 426 studies10+ countriesUpdated daily77 recruiting
VerifiedClinicalTrials.gov · WHO ICTRP · regional registries
426
Total trials
10+
Countries
10+
Sponsors
77
Recruiting
By phase
Phase 2164
N/A90
Phase 372
Phase 146
Early Phase 137
By status
Completed184
Recruiting77
Terminated50
Not yet recruit...44
Unknown42
Top countries
United States of America91
China46
South Korea20
Germany18
France14
Top sponsors
Boehringer Ingelhe...49
AstraZeneca21
Pfizer19
Hoffmann-La Roche13
Janssen Research &...12
Recent trials
Latest clinical trials for Carcinoma, Non-Small-Cell Lung
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression
Ruijin Hospital · China
NCT06269211Not yet recr...
- Phase
- Phase 2
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions
NCT06280196Not yet recr...
- Phase
- Phase 3
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
Ningbo No.2 Hospital
NCT06221462Not yet recr...
- Phase
- Phase 2
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Bristol-Myers Squibb · Argentina,Brazil,Canada,Chile,China,Germany,Hungary,Italy,Japan,Romania,Turkey,United States of Amer
NCT06140836Not yet recr...
- Phase
- Phase 3
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development...
NCT06120140Not yet recr...
- Phase
- Phase 2
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC
Kiromic BioPharma Inc.
NCT06069570Not yet recr...
- Phase
- Phase 1
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
Pfizer
NCT06075615Not yet recr...
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
AstraZeneca · Kuwait,Qatar,Saudi Arabia,United Arab Emirates
NCT06039683Recruiting
Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)
Assistance Publique - Hôpitaux...
NCT06068088Not yet recr...
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
NCT06012435Not yet recr...
- Phase
- Phase 3
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
AstraZeneca
NCT06008093Not yet recr...
- Phase
- Phase 3
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Qian Chu · China
NCT06001151Recruiting
- Phase
- Phase 2
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Merck Sharp & Dohme (I.A.) LLC · Australia;Brazil;Canada;Chile;China;Estonia;Germany;Greece;Israel;Italy;Japan;Latvia;Lithuania;Malay
PHRR230203-005387Ongoing
- Phase
- Phase 3
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Hunan Cancer Hospital · China
NCT05940532Recruiting
- Phase
- Phase 2
Metabolic Response to Food in Advanced Lung Cancer
Pennington Biomedical Research... · United States of America
NCT05937074Recruiting
National Network Genomic Medicine Lung Cancer, Germany
Prof. Dr. Juergen Wolf · Germany
NCT05934032Recruiting
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Janssen Research & Development... · Malaysia,South Korea,United States of America
NCT05908734Recruiting
- Phase
- Phase 1/2
CIETAI and Sequential Radiotherapy in Squamous Lung Cancer
Dong Wang · China
NCT05892237Not yet recr...
- Phase
- Phase 2
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
Hoffmann-La Roche
NCT05872763Not yet recr...
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
AstraZeneca · Japan
NCT05826366Recruiting
About this profile
Access comprehensive clinical trial information for Carcinoma, Non-Small-Cell Lung through Pure Global AI's free database. This collection includes 426 clinical trials across multiple phases including Phase 2, N/A, Phase 3. Currently, 77 trials are actively recruiting participants.
Research for Carcinoma, Non-Small-Cell Lung is being conducted in United States of America, China, South Korea and 7+ other countries. Leading sponsors include Boehringer Ingelheim and AstraZeneca. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Pure Global AI provides free access to 426 clinical trials studying Carcinoma, Non-Small-Cell Lung, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Boehringer Ingelheim, AstraZeneca, Pfizer, among others.